Advances In Anatomic Pathology最新文献

Advancing Digital Pathology With Large Language Models. 使用大型语言模型推进数字病理学。

IF 2.6 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-29 DOI: 10.1097/PAP.0000000000000505

Partha P Ray

引用次数: 0

The Role of the Surgical Pathologist in the Recognition of Hereditary Mesenchymal Neoplasms. 外科病理学家在遗传性间质肿瘤识别中的作用。

IF 2.6 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-28 DOI: 10.1097/PAP.0000000000000508

Emily M Hartsough, Yin P Hung

引用次数: 0

BAP1 Tumor Predisposition Syndrome. BAP1肿瘤易感综合征。

IF 2.6 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-28 DOI: 10.1097/PAP.0000000000000507

Rossana N Lazcano Segura, Mai P Hoang

引用次数: 0

An Approach to the Bone Marrow Workup and Diagnosis of Eosinophilia and Mast Cell Disorders. 嗜酸性粒细胞增多症和肥大细胞疾病的骨髓检查和诊断方法。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-01 Epub Date: 2025-03-27 DOI: 10.1097/PAP.0000000000000486

Kaaren K Reichard, Tracy I George, Daniel A Arber

{"title":"An Approach to the Bone Marrow Workup and Diagnosis of Eosinophilia and Mast Cell Disorders.","authors":"Kaaren K Reichard, Tracy I George, Daniel A Arber","doi":"10.1097/PAP.0000000000000486","DOIUrl":"10.1097/PAP.0000000000000486","url":null,"abstract":"The approach to eosinophilia and mast cell disorders in the bone marrow is diverse and depends on multiple factors including access to ancillary testing, resources to support testing, type of practice setting (eg, community, remote, tertiary care center or specialized referral center for these disorders) and whether there are options for clinical trial enrollment. That said, while there are some basic principles to the workup that we can all likely agree upon, individual practice habits will need to be tailored to suit an individual setting. As such, the approach presented in this manuscript is meant to serve as a practical guide and not as dogma per se. Importantly, an in-depth discussion of individual diseases and International Consensus Classification diagnostic criteria will not be covered, as the main focus of this article is the approach to these disorders. The reader is referred to a comprehensive discussion of these diseases and diagnostic criteria in several excellent articles. While there are clear areas of overlap between eosinophilia and mast cell conditions (eg, systemic mastocytosis associated with eosinophilia, myeloid neoplasm with eosinophilia, and tyrosine kinase rearrangements), it is the authors' opinion that it is perhaps easier to navigate these entities separately (eg, eosinophilia as one broad topic and mast cell conditions as another) and to recognize the settings in which overlap may exist and what testing might be considered. Eosinophilia and mast cell conditions will be discussed separately supplemented by generous use of figures and tables to highlight key points.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"259-271"},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Concepts in Histiocytic Neoplasms. 组织细胞肿瘤的最新概念。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-01 Epub Date: 2025-05-07 DOI: 10.1097/PAP.0000000000000499

Neval Ozkaya, Elaine S Jaffe

引用次数: 0

The Classification of Hematopoietic Neoplasms: The Why, How, and Who? 造血肿瘤的分类：为什么，如何分类，谁分类？

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1097/PAP.0000000000000503

Daniel A Arber, James R Cook

引用次数: 0

Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms. 骨髓增生性肿瘤和骨髓增生异常/骨髓增生性肿瘤的诊断方法。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-01 Epub Date: 2025-04-17 DOI: 10.1097/PAP.0000000000000493

Sonam Prakash, Attilio Orazi

{"title":"Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms.","authors":"Sonam Prakash, Attilio Orazi","doi":"10.1097/PAP.0000000000000493","DOIUrl":"10.1097/PAP.0000000000000493","url":null,"abstract":"The International Consensus Classification (ICC) updated in 2022 the World Health Organization (WHO) classification of hematopoietic tumors (2016 revision of the 4th edition WHO classification). Although the major categories of myeloid neoplasms remained unchanged from the prior WHO classification, many disease entities including those in the myeloproliferative neoplasm (MPN) and myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) categories underwent updates. For all these disease subtypes, a careful integration of clinicopathologic findings and molecular data led to improved diagnostic definitions. Although the classification of MPNs received only minor changes, these included a simpler definition of accelerated phase of chronic myeloid leukemia. For the MDS/MPN group, in addition to the presence of one or more increased peripheral blood cell counts as evidence of myeloproliferative features, concomitant cytopenia as evidence of ineffective hematopoiesis is now an explicit diagnostic requirement for all the entities included in this category. The presence of specific mutations in the appropriate clinicopathologic context is now included in the diagnostic criteria for some of the MPN and MDS/MPN entities. This review aims to briefly discuss the diagnostic approach to MPNs and MDS/MPNs according to the ICC.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"284-298"},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia. 骨髓增生异常综合征和急性髓系白血病的诊断谱。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-07-01 Epub Date: 2025-02-03 DOI: 10.1097/PAP.0000000000000485

Daniel A Arber, Attilio Orazi

{"title":"The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia.","authors":"Daniel A Arber, Attilio Orazi","doi":"10.1097/PAP.0000000000000485","DOIUrl":"10.1097/PAP.0000000000000485","url":null,"abstract":"The International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) expands on the work of prior classifications to refine the diagnostic criteria for MDS and AML and to identify specific genetic disease subtypes. This review summarizes the approach to the diagnosis of MDS and AML from the ICC perspective. For MDS, the significance of detecting mutations in SF3B1 , usually associated with ring sideroblasts, as well as the poor prognosis of mutations of TP53 are now included. For AML, new genetic categories are included, and the classification now incorporates additional clinically significant gene mutations by recognizing AML with TP53 mutation and AML with mutations in genes associated with prior therapy or MDS. Finally, the new category of MDS/AML is introduced for adult patients without recurrent de novo genetic abnormalities with 10% to 19% peripheral blood or bone marrow blasts that allow for more treatment flexibility based on clinical findings. While the increase in genetic categories and changes in blast cell requirements can be confusing, a stepwise approach is provided to allow easy use of the classification.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"299-306"},"PeriodicalIF":5.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Large Cell Neuroendocrine Carcinoma of the Lung: In Search for a Better Definition. 肺大细胞神经内分泌癌：寻找更好的定义。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-06-26 DOI: 10.1097/PAP.0000000000000504

David Suster, Saul Suster

引用次数: 0

Molecular Advances in Cholestatic Liver Diseases. 胆汁淤积性肝病的分子研究进展。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2025-06-16 DOI: 10.1097/PAP.0000000000000502

Raima Memon, Romil Saxena

{"title":"Molecular Advances in Cholestatic Liver Diseases.","authors":"Raima Memon, Romil Saxena","doi":"10.1097/PAP.0000000000000502","DOIUrl":"https://doi.org/10.1097/PAP.0000000000000502","url":null,"abstract":"The list of genetically defined causes of cholestatic liver diseases continues to expand; it currently includes mutations affecting bile acid synthesis, basolateral and apical membrane transporters, bile duct development, canalicular tight junctions, and bile acid conjugation, among others. The most frequently identified mutations in large multi-institutional studies of cholestasis occur in JAG1, ATP8B1, ABCB11, ABCB4, SERPINA1, and CFTR. Mutations in JAG1, SERPINA1, and CFTR cause Alagille syndrome, alpha-1 antitrypsin deficiency, and cystic fibrosis, respectively. Mutations in ATP8B1, ABCB11, and ABCB4 cause a spectrum of diseases that range from the episodic, nonprogressive benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy to the severe and rapidly progressive familial intrahepatic cholestasis. These cholestatic disorders present a wide range of symptoms and overlapping clinical features. However, in contemporary practice, diagnosis is often easily and rapidly established by clinically available comprehensive gene panels. In addition to diagnosis, these panels also aid in the discovery of novel genes or variants as potential causes of cholestasis. Genetic mutations may also be responsible for drug-induced cholestasis, as the liver plays a vital role in metabolism of drugs and xenobiotics. Uptake into hepatocytes and elimination into the bloodstream or bile of drugs and xenobiotics involve transporters across the basolateral and apical hepatocellular membranes, respectively. Therefore, mutations in any of the transporters lead to impaired metabolism and/or elimination of these substances. Furthermore, a large number of drugs and xenobiotics have a transcriptional or functional inhibitory effect on transporters such as BSEP and MDR3, setting the stage for the all-too-common drug-induced cholestasis.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0